KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Capital Expenditures (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Capital Expenditures for 17 consecutive years, with $370.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 2.12% to $370.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 5.05% increase, with the full-year FY2025 number at $1.3 billion, up 5.05% from a year prior.
  • Capital Expenditures was $370.0 million for Q4 2025 at Bristol Myers Squibb, up from $320.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $378.0 million in Q4 2024 to a low of $173.0 million in Q1 2021.
  • A 5-year average of $293.0 million and a median of $281.0 million in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 76.47% in 2021, then dropped 8.52% in 2022.
  • Bristol Myers Squibb's Capital Expenditures stood at $320.0 million in 2021, then increased by 8.12% to $346.0 million in 2022, then fell by 4.62% to $330.0 million in 2023, then rose by 14.55% to $378.0 million in 2024, then fell by 2.12% to $370.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Capital Expenditures are $370.0 million (Q4 2025), $320.0 million (Q3 2025), and $361.0 million (Q2 2025).